VIR-1388

Phase 1Biologic

NNational Institute of Allergy and Infectious Diseases (NIAID)

VIR-1388 is one of 2 biologic programs targeting Cytomegalovirus (CMV). It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cytomegalovirus (CMV)Not yet recruiting

Cytomegalovirus (CMV)Phase 1

Not yet recruiting

Competition

Competitive Landscape

2 competitors in Cytomegalovirus (CMV)

#DrugCompanyPhaseTrials

Viral Ctls

NNew York Medical College

Phase 2

1 2

VIR-1388

NNational Institute of Allergy and Infectious Diseases (NIAID)

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 1Not yet recruiting

Cytomegalovirus (CMV)

NCT07801456

Clinical

Trials by Indication[1]

Immunogenicity1 trial

To Investigate Safety, Reactogenicity and Immunogenicity of VIR-1388 Compared With Placebo in Participants Without HIV

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT05854381·93 enrolled

Cytomegalovirus (CMV)1 trial

A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of a Higher Dose of the HCMV-HIV Vaccine Candidate VIR-1388, in HCMV-seropositive Adult Participants Without HIV

Not yet recruiting·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT07801456·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for VIR-1388. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — VIR-1388 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for VIR-1388. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Institute of Allergy and Infectious Diseases (NIAID) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: NNational Institute of Allergy and Infectious Diseases (NIAID)

VIR-1388

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Immunogenicity1 trial

Cytomegalovirus (CMV)1 trial

References

Drug Info

Quick Facts

Related News